Donate

Play Live Radio

Next Up:

0:00

0:00 0:00

Available On Air Stations

Thank you!

Thank you to everyone who donated, volunteered, sent words of encouragement or otherwise supported us during fall pledge week. You make Montana Public Radio possible!

Thanks to your generosity, we've raised $382,000 toward our $400,000 fall fundraising goal! We could not do this work without you and we are deeply grateful for your support.

Merck's melanoma vaccine trial shows reduced recurrence or death from skin cancer

NPR | By Yuki Noguchi

Published October 26, 2026 at 2:42 AM MDT

Merck presented its mRNA melanoma vaccine trial data at a European cancer conference this weekend. Results are promising: The vaccine reduces recurrence and death alongside an immunotherapy drug.

Yuki Noguchi

Yuki Noguchi is a correspondent on the Science Desk based out of NPR's headquarters in Washington, D.C.

Make a monthly donation

Become a sustaining member for as low as $5/month

Make a one-time donation

Make an annual or one-time donation to support MTPR

Pay pledge or update info

Pay an existing pledge or update your payment information